Category: Uncategorized

For laboratory research use only. GHK-Cu is not a drug, dietary supplement, or cosmetic ingredient supplied for human or veterinary use, and nothing below is a recommendation for administration to humans or animals.

GHK-Cu is the copper(II) coordination complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). The peptide sequence was first isolated from human plasma albumin fractions in the early 1970s, and the copper complex has since become one of the most extensively characterized small peptide–metal systems in extracellular matrix and dermal fibroblast research. This overview summarizes what preclinical literature reports about its chemistry and studied mechanisms, and how the copper-bound and copper-free forms differ as laboratory materials.

Structure and copper coordination

GHK is a three-residue peptide (Gly-His-Lys) with a molecular weight of roughly 340 Da. Its architecture gives it an unusually well-defined metal-binding site: the N-terminal amine, the imidazole nitrogen of histidine, and a deprotonated backbone amide nitrogen together form a square-planar chelation geometry around Cu(II), with the lysine side chain remaining free and positively charged at physiological pH. The resulting 1:1 complex has a molecular weight near 402 Da and is visibly blue-violet in aqueous solution.

Because the affinity of GHK for Cu(II) is high but not irreversible, the literature discusses the complex primarily as a copper shuttle rather than a copper sink — a carrier able to exchange copper with plasma proteins and with cellular uptake machinery. That framing matters mechanistically, because several enzymes involved in matrix assembly and redox regulation are cuproenzymes, including lysyl oxidase and Cu/Zn superoxide dismutase. Researchers investigating GHK-Cu therefore generally treat copper delivery and peptide signaling as two coupled variables rather than one, and copper-free GHK is frequently run as a comparator for exactly this reason.

Reported plasma concentrations of the free tripeptide are often cited as declining with donor age — on the order of 200 ng/mL in young adults versus roughly 80 ng/mL by the sixth decade. This observation is descriptive rather than causal, but it is the origin of much of the interest in the sequence as an endogenous signaling fragment.

Mechanisms studied in preclinical research

Extracellular matrix turnover

The earliest mechanistic work examined cultured fibroblasts. Maquart and colleagues reported in the late 1980s that GHK-Cu increased collagen synthesis in fibroblast culture at nanomolar to micromolar concentrations. Later work from the same group examined proteoglycan and glycosaminoglycan expression, reporting changes in decorin and related small proteoglycans in wound-model tissue exposed to the complex. Decorin is of mechanistic interest because it participates in collagen fibril organization and in sequestering TGF-β, placing it upstream of matrix architecture rather than simply being a structural output.

A related line of research examined matrix metalloproteinases. Siméon and colleagues reported that GHK-Cu modulated MMP-2 alongside its tissue inhibitors TIMP-1 and TIMP-2 in fibroblast culture. Because both the protease and its inhibitors moved, the reported profile is generally interpreted as increased matrix turnover — coordinated breakdown and resynthesis — rather than one-directional accumulation or degradation. This is the mechanistic claim most consistently supported across the in vitro literature.

Gene-expression profiling

Interest broadened considerably after transcriptomic datasets became available. Pickart and colleagues analyzed GHK against reference expression signatures using the Broad Institute Connectivity Map and reported that the peptide was associated with modulation of several thousand human genes in cultured cells at low-micromolar exposures, with enrichment in categories related to matrix remodeling, DNA repair, ubiquitin–proteasome activity, and inflammatory signaling. These are correlative signature analyses, not demonstrations of a single receptor or pathway, and no canonical GHK receptor has been established. Researchers designing follow-up work generally treat the gene-signature literature as hypothesis-generating.

Redox and inflammatory markers

GHK-Cu has been described in vitro as possessing superoxide-dismutase-like activity, consistent with the redox behavior of a chelated Cu(II) center. Separate cell-culture reports have examined effects on inflammatory cytokine markers such as TNF-α and IL-6 in fibroblast systems. Copper chemistry cuts both ways here: chelated copper can attenuate free-radical chemistry at low concentrations while free or loosely bound copper can catalyze Fenton-type reactions. Concentration and complex integrity are therefore critical experimental variables, and studies that do not report copper speciation are difficult to interpret.

Animal wound-model work

Topical GHK-Cu has been evaluated in rodent, rabbit, and canine wound models, where investigators have reported differences in closure kinetics and granulation-tissue characteristics relative to vehicle controls. These studies are small, heterogeneous in formulation and endpoint definition, and not consistently blinded, so they are best read as supporting the matrix-turnover mechanism rather than as outcome evidence.

GHK versus GHK-Cu as research materials

Both forms are sold and studied, and they are not interchangeable in an assay. The table below summarizes the practical differences.

Product pages for both forms are here: GHK-Cu and GHK (basic).

Laboratory handling and solution preparation

Lyophilized material is normally stored cold, desiccated, and protected from light, with reconstituted stock treated as short-lived. For the copper complex, color is a useful qualitative indicator: loss of the characteristic blue tint, or precipitate formation, suggests copper dissociation or degradation of the complex and argues for preparing fresh stock rather than proceeding. Strongly alkaline buffers and competing chelators such as EDTA will perturb the complex and should be accounted for in buffer selection.

Concentration work is ordinary laboratory arithmetic: diluent volume divided into peptide mass gives the stock concentration, from which working dilutions follow. The reconstitution calculator handles this conversion. Note that for GHK-Cu, molar calculations should use the complex mass, not the free-peptide mass — a roughly 18% difference that is easy to overlook and that shifts every downstream molarity.

Limitations of the evidence base

Three caveats recur across this literature. First, the great majority of mechanistic data comes from fibroblast culture and small-animal models; extrapolation beyond those systems is not supported. Second, no defined receptor has been identified, so “mechanism” here means observed pathway and expression changes, not a resolved signaling cascade. Third, results are sensitive to copper speciation, peptide purity, and salt form — which is why analytical documentation matters. Batch-level identity and purity data are published in the COA library.

Reviewed for research accuracy: July 30, 2026.

References

• Pickart L, Thaler MM. Nature New Biology. 1973;243:85–87. (Original isolation of the GHK sequence from human plasma.)
• Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. FEBS Letters. 1988;238(2):343–346.
• Siméon A, Emonard H, Hornebeck W, Maquart FX. Life Sciences. 2000;67(18):2257–2265.
• Siméon A, Monier F, Emonard H, et al. Journal of Investigative Dermatology. 2000. (Glycosaminoglycan and small-proteoglycan expression in wound models exposed to the tripeptide–copper complex.)
• Pickart L, Vasquez-Soltero JM, Margolina A. BioMed Research International. 2015;2015:648108. DOI: 10.1155/2015/648108.
• Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29986520. DOI: 10.3390/ijms19071987.
• Cangul IT, Gul NY, Topal A, Yilmaz R. BMC Veterinary Research. 2006;2:29. (Comparative open-wound model evaluation of a tripeptide–copper complex.)
• Additional preclinical reports have examined GHK and GHK-Cu effects on inflammatory cytokine markers in fibroblast culture; these are small single-laboratory studies and are cited here generically.

Research use only. All compounds discussed are supplied strictly for in vitro laboratory and preclinical research by qualified personnel, and are not for human consumption, therapeutic use, cosmetic use, or veterinary application.

Research use only. TB-500 (thymosin beta-4) is supplied strictly for in vitro laboratory research and is not for human or veterinary use, food, or drug applications.

Thymosin beta-4 (Tβ4) is among the most abundant small peptides in mammalian cells, and it is one of the few whose primary biochemical function has been characterized in unusual detail: it binds monomeric actin. That single property — sequestration of the globular (G-actin) pool — anchors most of the mechanistic literature, and it is the reason the peptide appears so often in cytoskeletal and cell-migration research. This overview summarizes what the preclinical record describes about structure, actin binding, migration assays, and the study contexts in which Tβ4 has been examined.

Reviewed for research accuracy: July 30, 2026

What the TB-500 designation actually refers to

“TB-500” is a supply-chain designation rather than a formal pharmacological name, and the distinction matters for experimental design. Material offered under that label is most often a short synthetic peptide corresponding to the actin-binding region of Tβ4 — commonly the acetylated sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) — whereas the large majority of peer-reviewed studies the designation borrows from were performed with full-length, 43-residue thymosin beta-4.

The two are not interchangeable in a research setting. A fragment containing the binding motif can reproduce some actin-related behavior in vitro, but full-length Tβ4 carries additional sequence implicated in extracellular signaling and in generating downstream fragments. Researchers should confirm from the certificate of analysis which sequence and molecular weight they are actually working with before mapping their results onto published findings.

Structure and the LKKTET motif

Full-length Tβ4 is a 43-amino-acid, strongly acidic peptide of roughly 4.9 kDa. In free solution it is largely unstructured — an intrinsically disordered peptide — and studies indicate it adopts partial helical character upon binding actin. The central hexapeptide motif LKKTET, located around residues 17–22, is conserved across the β-thymosin family and has been identified in structural and mutagenesis work as essential to the actin interaction. Sequences marketed under the TB-500 designation are built around this motif.

Actin sequestration: the primary characterized mechanism

Tβ4 was originally isolated as the cytosolic factor responsible for maintaining a large pool of unpolymerized actin. It binds G-actin in an approximately 1:1 complex with reported affinities in the low micromolar range, and the bound monomer is inhibited from adding to filament ends. Functionally, this makes Tβ4 a buffer on the monomer–filament equilibrium rather than an active remodeler.

That places it in a distinct category from other actin-binding proteins studied alongside it:

• Profilin also binds monomers but delivers them to barbed filament ends, promoting elongation rather than withholding it.
• Gelsolin and cofilin act on filaments — severing and, in cofilin’s case, accelerating depolymerization.
• Tβ4 holds monomers in reserve, and research suggests the size of that reserve influences how quickly a cell can mount localized polymerization.

Because the sequestered pool can be released as free monomer concentration drops, the model that emerges from in vitro work is one of a rapidly mobilizable actin store — a plausible mechanistic bridge between Tβ4 levels and the cytoskeletal reorganization that precedes cell movement.

Cell migration research

Migration is where Tβ4 has been examined most consistently. In cultured endothelial cells, preclinical studies have reported increased directional migration in Boyden-chamber and scratch-closure assays following exposure to the peptide. Comparable migration readouts have been described in keratinocyte and corneal epithelial models, where investigators have also examined changes in cell-matrix adhesion components such as laminin-5.

Signaling work has looked beyond the cytoskeleton itself. In a widely cited cardiac cell study, Tβ4 was reported to associate with integrin-linked kinase (ILK) and downstream Akt phosphorylation, and the observed migratory effects were attenuated when that pathway was disrupted — evidence that at least part of the phenotype in those models is signaling-mediated rather than a direct consequence of monomer sequestration. These findings are from animal and cell-culture systems; they have not been established in humans.

Extracellular behavior and the Ac-SDKP fragment

Tβ4 lacks a classical secretion signal sequence, yet extracellular peptide has been detected in wound fluid and plasma in animal studies, and non-classical release has been proposed. No definitive high-affinity receptor for extracellular Tβ4 has been established, which remains one of the notable gaps in the mechanistic account.

A related line of research concerns Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro), an N-terminal tetrapeptide that prolyl oligopeptidase can liberate from Tβ4. Ac-SDKP has been studied independently in angiogenesis and fibrosis models, meaning some effects attributed to full-length Tβ4 in vivo may reflect the activity of this cleavage product. A fragment such as Ac-LKKTETQ cannot generate it — another reason sequence identity should be verified before comparing results across studies.

Study contexts at a glance

Laboratory handling and preparation arithmetic

Both the full-length peptide and its short fragments are highly water-soluble owing to their acidic character, and are typically supplied lyophilized. Standard practice for lyophilized research peptides applies: store the sealed vial cold and protected from light, allow it to reach room temperature before opening to limit condensation, reconstitute gently down the vial wall without vortexing, and aliquot to avoid repeated freeze–thaw cycles of the stock.

Concentration arithmetic for preparing stock solutions is straightforward. A 5 mg lyophilate brought up in 2 mL of diluent yields a 2.5 mg/mL stock; 100 µL of that stock therefore contains 250 µg of peptide. The reconstitution calculator handles the same arithmetic for other vial sizes and target working concentrations. This is laboratory dilution math for preparing in vitro stocks only.

For assay work, purity and identity data matter more than nominal label strength. HPLC purity, mass-spectrometric confirmation of the expected molecular weight, and — for any cell-based system — endotoxin status are the parameters most likely to explain irreproducible migration results between labs.

Limitations in the current literature

Several caveats recur across reviews. The overwhelming majority of published findings come from cell-culture and rodent models, and human data remain limited. Extracellular signaling is described phenomenologically because no receptor has been definitively identified. Reported effects vary substantially with model system, peptide form, and concentration range. And the fragment-versus-full-length distinction is frequently blurred in secondary sources, which propagates comparisons that the primary literature does not support. Researchers designing new work should specify which construct they are using and cite primary studies performed with that same construct.

References

• Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. Int J Biochem Cell Biol. 2001;33(3):205–220. PMID: 11311852. (Review of β-thymosin structure and actin-sequestering function.)
• Goldstein AL, Hannappel E, Kleinman HK. Trends Mol Med. 2005;11(9):421–429. PMID: 16099219.
• Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Nature. 2004;432(7016):466–472. PMID: 15565145. (ILK/Akt signaling and cell migration in cardiac models.)
• Safer D, Elzinga M, Nachmias VT. J Biol Chem. 1991. (Identification of thymosin β4 as the actin-sequestering factor previously designated Fx.)
• Malinda KM, Goldstein AL, Kleinman HK. FASEB J. 1997. (Directional migration of human umbilical vein endothelial cells in vitro.)
• Sosne G and colleagues, corneal epithelial migration and inflammatory-marker studies in animal and cell-culture models, Experimental Eye Research and Experimental Cell Research, 2002–2010.
• Preclinical investigations of Ac-SDKP, the N-terminal tetrapeptide released from Tβ4 by prolyl oligopeptidase, in angiogenesis and fibrosis models (multiple groups; summarized in β-thymosin review volumes of Annals of the New York Academy of Sciences).

Note on citations: verbatim article titles are omitted where a title contains clinical-outcome language. Authors, journal, year, and PMID resolve each record. No identifier here is approximated — where a specific PMID could not be confirmed, the finding is cited by author, journal, and year only.

Research use only. The information above summarizes published preclinical literature for laboratory reference and makes no therapeutic, diagnostic, or performance claim. TB-500 (thymosin beta-4) is not for human or veterinary use, food, or drug applications.

Research use only: BPC-157 is supplied strictly for in vitro and laboratory research and is not intended for human or veterinary use, food, or any diagnostic or therapeutic application.

BPC-157 is one of the most frequently studied synthetic peptides in the preclinical tissue-repair literature, with published work spanning in vitro cell culture, rodent injury models, and mechanistic signaling studies. Its prominence in the literature is not the same thing as clinical validation, and the two are easy to conflate. This overview summarizes what the peer-reviewed preclinical record actually describes, what remains unestablished, and how laboratories typically characterize and handle the material.

Molecular identity

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), corresponding to a partial sequence of a protein isolated from human gastric juice. Its molecular formula is C₆₂H₉₈N₁₆O₂₂ with a monoisotopic mass near 1419.5 Da. The BPC designation refers only to the parent protein from which the fragment was derived; it carries no established meaning about activity in any organism.

Two physicochemical properties explain much of its experimental popularity. First, it is freely soluble in water and requires no organic co-solvent or acidification for reconstitution. Second, it has been reported to remain intact in human gastric juice in vitro for extended periods without an added protease inhibitor, which is why a large share of the rodent literature uses oral-gavage or drinking-water administration protocols alongside parenteral routes. Researchers designing comparative work should note that this route heterogeneity is a persistent confound when reading across studies.

Mechanisms examined in preclinical research

Angiogenic signaling

The best-characterized mechanistic thread involves vascular endothelial growth factor receptor 2 (VEGFR2). In endothelial cell work, BPC-157 exposure has been associated with VEGFR2 activation and internalization and with downstream Akt–eNOS signaling, with tube-formation and endothelial migration endpoints reported as concentration-dependent. Reviews from the primary research groups describe a related phenomenon in whole-animal vascular models, where collateral vessel recruitment has been observed following experimental vessel occlusion. These are model-system observations, not demonstrated outcomes in humans.

Nitric oxide system interaction

A recurring experimental design in the rodent literature pairs BPC-157 with the NOS inhibitor L-NAME and with the NO precursor L-arginine. Across these studies, the peptide is reported to counteract several L-NAME-induced effects, which the authors interpret as an interaction with NO-system regulation rather than direct NOS agonism. The mechanism remains inferential; the studies establish an interaction pattern, not a binding target.

Fibroblast outgrowth, migration, and adhesion signaling

In tendon fibroblast explant and culture systems, BPC-157 exposure has been observed to increase cell outgrowth, survival under serum-deprived conditions, and migration, with increased phosphorylation of focal adhesion kinase (FAK) and paxillin reported as the associated signaling change. A separate study from the same group reported increased growth hormone receptor expression in tendon fibroblasts following exposure, suggesting a possible sensitization mechanism rather than a direct growth-factor-like action.

Early growth response and matrix organization

Preclinical work in rodent granulation-tissue models has examined Egr-1 expression and downstream collagen organization as candidate mediators. This line of inquiry is less developed than the VEGFR2 work and rests on a smaller number of independent replications.

Central and enteric signaling

Review literature describes reported interactions with dopaminergic and serotonergic systems in rodent CNS models, framed by the authors within a gut–brain axis hypothesis. This area is largely descriptive and hypothesis-generating at present.

Reported model systems at a glance

What the literature does not establish

Three limitations should shape how any researcher reads this body of work.

• Publication concentration. A substantial fraction of the in vivo literature originates from a single research group and its collaborators. Independent replication exists but is thinner than the raw citation count implies, and meta-analytic aggregation of these studies is not currently meaningful.
• Human data are minimal. Early-phase human investigation of a related formulation (PL 14736) has been reported, but published, peer-reviewed human evidence remains limited. No published human study establishes safety, pharmacokinetics, or effect in a way that supports extrapolation from the rodent record.
• Endpoint heterogeneity. Concentrations, routes, vehicles, and outcome measures vary widely between studies, which makes cross-study comparison unreliable and complicates any attempt to identify a concentration–response relationship in vitro.

Investigators should also be aware that BPC-157 appears on the World Anti-Doping Agency Prohibited List under the S0 non-approved substances category, a status that is relevant to institutional and regulatory review of any research protocol involving it.

Handling and storage in the laboratory

Lyophilized BPC-157 is typically stored at −20 °C or below, protected from light and moisture, and allowed to equilibrate to room temperature before the vial is opened so that condensation does not enter the powder. Reconstituted solutions are generally held at 2–8 °C and used within a short working window; repeated freeze–thaw cycles are a common source of assay variability and are best avoided by aliquoting after reconstitution.

When adding solvent, directing it down the inner wall of the vial rather than onto the powder cake reduces mechanical stress on the peptide. Vortexing is unnecessary — gentle swirling until the cake dissolves is sufficient for a water-soluble peptide of this size.

Reconstitution is straightforward laboratory arithmetic. A 5 mg lyophilized quantity brought up in 2 mL of bacteriostatic water yields a 2.5 mg/mL stock, so a 0.1 mL withdrawal contains 250 µg of peptide. Researchers who prefer to work backward from a target concentration can use the peptide reconstitution calculator to derive the solvent volume.

Analytical verification

Because sequence identity and purity directly determine whether an experiment is interpretable, third-party analytical documentation should be checked before material enters a protocol. HPLC purity and mass spectrometry confirming the expected mass are the two minimum data points. Batch-level reports are published in the COA library, and product-specific documentation is linked from the BPC-157 product page.

References

• Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. J Appl Physiol. 2011;110(3):774–780. PMID: 21030672.
• Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMID: 25415472.
• Hsieh MJ, et al. J Mol Med (Berl). 2017;95(3):323–333. PMID: 27847966.
• Huang T, et al. Drug Des Devel Ther. 2015;9:2485–2499. PMID: 25995620.
• Seiwerth S, et al. Curr Pharm Des. 2018;24(18):1972–1989. PMID: 29998800.
• Sikirić P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857–865. PMID: 27138887.
• Gwyer D, Wragg NM, Wilson SL. Cell Tissue Res. 2019;377(2):153–159. PMID: 30915550.
• Additional preclinical studies have examined the interaction of BPC-157 with the L-arginine/NO pathway in rodent models using L-NAME co-administration designs; these are catalogued within the review literature cited above.

Reviewed for research accuracy — July 30, 2026.

Research use only: the material described here is intended solely for laboratory research by qualified investigators. It is not a drug, supplement, or medical device, and is not for human or veterinary consumption or administration.

The information below is provided strictly for laboratory research and educational purposes; Adipotide (FTTP) is not approved for human or veterinary use, diagnosis, or treatment.

Adipotide, frequently written as FTTP and cataloged for research as a prohibitin-targeting peptidomimetic, is one of the more mechanistically distinctive compounds studied in adipose-vascular biology. Unlike receptor-agonist peptides, Adipotide was designed as a two-domain chimeric molecule that couples a vascular-homing motif to a proapoptotic effector. This overview summarizes what the FTTP designation refers to, how the CKGGRAKDC targeting motif is understood to engage prohibitin, and the preclinical contexts in which researchers have examined the molecule. All observations described here derive from animal-model and in vitro literature.

What the FTTP designation refers to

In the research literature, FTTP is treated as a functional label rather than a formal chemical name. The molecule is also referenced as adipotide and, in early work, as prohibitin-targeting peptide-1 (PTP-1). Structurally, it is a bipartite construct: a short targeting peptide fused through a glycinyl linker to a synthetic proapoptotic sequence. The design intent, as reported by its originators, was to direct a membrane-disrupting effector specifically toward the microvasculature that supplies white adipose tissue in research models, rather than acting on adipocytes directly.

The CKGGRAKDC targeting motif and prohibitin

The targeting arm of Adipotide is the cyclic nonapeptide CKGGRAKDC. In phage-display screening of vascular beds, this motif was identified as binding prohibitin, a conserved chaperone protein that is typically mitochondrial but that has been reported on the luminal surface of endothelial cells associated with white fat in animal models. Prohibitin’s appearance as a cell-surface marker in this vascular compartment is what gave the motif its apparent selectivity in preclinical studies: researchers observed the peptide accumulating in adipose-associated vasculature rather than distributing uniformly across tissues.

It is worth emphasizing that prohibitin biology is complex and context-dependent. Its role as an accessible surface receptor has been characterized primarily in rodent and non-human primate vasculature, and the degree to which the CKGGRAKDC interaction generalizes across species remains an open research question rather than a settled fact.

The proapoptotic domain mechanism

The effector arm is D(KLAKLAK)₂, a D-amino-acid form of a synthetic amphipathic peptide. In isolation this sequence is comparatively inert toward intact cells because it does not readily cross the plasma membrane. Preclinical work indicates that once the targeting motif promotes internalization, the (KLAKLAK)₂ domain interacts with the negatively charged mitochondrial membrane, disrupting membrane integrity and initiating the intrinsic apoptotic cascade. The D-amino-acid configuration was reportedly chosen to reduce proteolytic degradation. The same proapoptotic module has been examined in other targeted constructs in the oncology literature, which is where its mitochondrial mechanism was first described.

The conceptual model that emerges from this literature is a conditional one: the effector is understood to become active predominantly where the targeting motif concentrates it. Researchers have framed Adipotide as a proof-of-concept for ligand-directed apoptosis of a supporting vascular bed rather than of the parenchymal cells themselves.

Preclinical research contexts

Two bodies of animal-model work anchor most discussion of FTTP. The foundational rodent study characterized targeted ablation of adipose vasculature and the associated changes in adipose tissue in the animal models studied, with the authors describing apparent reversibility and resorption of adipose depots. A later study extended the same targeting approach to a non-human primate model, characterizing the compound’s distribution and its handling by the kidney. The reported endpoints are properties of those specific animal models and are not evidence of any effect in humans.

These findings are frequently cited precisely because they illustrate an unusual mechanism — acting on the vascular supply of a tissue — not because they establish any outcome outside the animal models studied. Renal exposure in particular has been flagged in the primate literature as a key parameter researchers monitor, underscoring that the compound’s biodistribution is an active subject of study rather than a resolved one.

Handling and characterization for research use

Adipotide is typically supplied as a lyophilized powder for laboratory reconstitution. Researchers planning in vitro or animal-model work generally document lot identity against a certificate of analysis and calculate working concentrations as straightforward laboratory arithmetic. Luxe Peptides provides third-party analytical documentation through its COA library, and molar and mass conversions for reconstitution can be worked through with the peptide reconstitution calculator. Product details for the research material are available on the Adipotide (FTTP) listing.

Research status and limitations

Adipotide has not advanced to any approved application, and the available data remain overwhelmingly preclinical. Species differences in prohibitin surface expression, the compound’s renal handling, and questions about durability of any observed effects all remain open. For researchers, the value of FTTP lies in what it demonstrates about ligand-directed apoptosis and vascular targeting as experimental strategies — not in any inference about human physiology, which the current literature does not support.

References

• Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Nat Med. 2004;10(6):625–632. PMID: 15133506.
• Barnhart KF, Christianson DR, Hanley PW, et al. Sci Transl Med. 2011;3(108):108ra112. PMID: 22072637.
• Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5(9):1032–1038. PMID: 10470080.
• Reviews of prohibitin as a multifunctional chaperone and its reported cell-surface roles provide additional background on the CKGGRAKDC target (see prohibitin biology literature in J Cell Mol Med and related journals).

Reviewed for research accuracy — 2026-07-13. This article is for laboratory research and educational use only. Adipotide (FTTP) is not a drug, supplement, or medical product and is not intended for human or animal administration, diagnosis, treatment, or prevention of any condition.

The information below is provided strictly for laboratory and educational research use only; ATX-304 (O-304) is not a drug, dietary supplement, or product for human or veterinary use.

Researchers searching for “ATX-304 peptide” or “what is ATX 304” are frequently working from a misconception worth correcting at the outset: ATX-304 is not a peptide. It is a small-molecule compound — a synthetic organic activator of AMP-activated protein kinase (AMPK) — and it is more widely referenced in the literature under its original designation, O-304 (also written O304). This guide summarizes the naming, the AMPK mechanism it is studied for, and the preclinical research contexts in which it has appeared.

ATX-304 vs. O-304: the same molecule, two designations

The two names refer to a single chemical entity. O-304 is the original research code under which the compound was first characterized as a direct pan-AMPK activator in metabolic and vascular animal models, and it remains the identifier most often used in the peer-reviewed literature. ATX-304 is a later development-stage designation applied to the same molecule as it moved into subsequent research programs. When evaluating sources, researchers should treat “O-304,” “O304,” and “ATX-304” as interchangeable labels for the same small molecule rather than as distinct compounds.

Because the “-304” suffix and the presence of the compound in metabolic research have led some vendors and search queries to file it alongside peptides such as GLP receptor agonists, it is worth restating: the mechanism described here is enzyme activation by a small molecule, not receptor agonism by a peptide.

What AMPK is, and why it is studied

AMPK is a heterotrimeric enzyme — assembled from a catalytic α subunit and regulatory β and γ subunits — that acts as a central cellular energy sensor. In research models, AMPK is described as becoming active when the cellular ratio of AMP (and ADP) to ATP rises, signaling low energy availability. Once active, the kinase has been observed in preclinical work to shift cells toward energy-producing (catabolic) pathways and away from energy-consuming (anabolic) ones: promoting glucose uptake and fatty-acid oxidation while restraining synthesis of lipids and glycogen. Canonical activation involves phosphorylation of a threonine residue (Thr172) on the α subunit by upstream kinases.

Multiple subunit combinations (isoforms) exist, and their tissue distribution differs, which is why the selectivity profile of any given activator matters to researchers designing experiments.

How ATX-304 (O-304) is described mechanistically

O-304 is characterized in the literature as a direct, pan-AMPK activator. Two features define that description:

• Direct — it is reported to bind and activate the AMPK complex itself, rather than acting indirectly by depleting cellular ATP the way older experimental tools such as metformin or AICAR are understood to work in research systems.
• Pan — it is described as activating a broad range of AMPK isoform combinations rather than a single α/β/γ assembly. Mechanistically, direct activators of this class are studied for their ability to promote AMPK activity in part by protecting the Thr172 phosphorylation site from dephosphorylation, stabilizing the active form of the enzyme.

This combination — direct binding plus broad isoform coverage — is the property that has made O-304 of interest as a research probe for AMPK biology across tissues, and it distinguishes it from more isoform-selective experimental activators.

Preclinical and early research contexts

O-304 has been examined primarily in two overlapping areas of preclinical research: metabolic and vascular/microvascular biology.

In rodent models, studies have reported that O-304 administration is associated with increased glucose uptake in skeletal muscle and altered hepatic glucose handling, consistent with the expected downstream consequences of AMPK activation. In the same body of work, researchers have also examined effects on microvascular perfusion, reporting improved capillary blood flow in animal models — a vascular readout that is mechanistically distinct from the metabolic endpoints and that has driven interest in AMPK activation beyond glucose handling alone.

Limited human data exist. An early-phase clinical study accompanying the principal preclinical report examined markers of glucose homeostasis in participants, but the human dataset is small and preliminary, and findings from it should be read as exploratory rather than established. Beyond metabolism and vasculature, AMPK activators as a class have been explored in a range of additional preclinical contexts — including skeletal-muscle and cardiac research models — where the enzyme’s role in energy balance is under investigation. Researchers should note that broad, direct AMPK activation has also been studied for potential off-target consequences in some tissues, which is an active area of experimental characterization.

ATX-304 (O-304) at a glance

Practical notes for researchers

Because O-304 is a small molecule rather than a peptide, researchers sourcing it for in vitro or animal-model work should confirm identity and purity against a certificate of analysis before use. Solubility and reconstitution parameters differ from those of the lyophilized peptides more commonly discussed in this space; any reconstitution figures should be treated purely as laboratory concentration arithmetic. Luxe Peptides publishes third-party analytics in its COA library, and the reconstitution calculator can assist with concentration math for laboratory preparation. The research compound itself is listed on the O-304 (ATX-304) product page.

References

• Steneberg P, Lindahl E, Dahl U, et al. JCI Insight. 2018;3(12):e99114. doi:10.1172/jci.insight.99114
• Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–262. doi:10.1038/nrm3311
• Myers RW, Guan HP, Ehrhart J, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science. 2017;357(6350):507–511. doi:10.1126/science.aah5582
• Additional preclinical studies have examined direct AMPK activators across skeletal-muscle, cardiac, and vascular models; researchers are encouraged to consult primary literature indexed under “O304” and “AMPK activator” in PubMed for the most current characterization.

Reviewed for research accuracy — published 2026-07-13. This article is provided for laboratory and educational research use only. ATX-304 (O-304) is not approved for human or veterinary use, and nothing here should be interpreted as medical, therapeutic, or dosing guidance.

For research use only. The following is an educational summary of peptide mechanisms studied in preclinical and laboratory settings; it is not medical guidance and describes no human use.

Growth-hormone (GH) secretagogue blends pair two classes of signaling molecule that act on distinct receptors along the somatotroph axis. In the research literature, one axis is a growth-hormone-releasing-hormone (GHRH) receptor agonist and the other is a growth-hormone secretagogue-receptor (GHS-R1a, the ghrelin receptor) agonist. The two blends researchers most often compare — Tesamorelin + Ipamorelin (TESA/IPA) and CJC-1295 + Ipamorelin (CJC/IPA) — share the same GHS-R component (ipamorelin) and differ almost entirely in the GHRH analog chosen. This article describes what that single substitution changes at the receptor and pharmacokinetic level, in research models only.

The shared component: ipamorelin

Both blends use ipamorelin as the GHS-R1a agonist. In preclinical characterization, ipamorelin has been described as a selective pentapeptide secretagogue that stimulates somatotroph signaling with comparatively little effect on cortisol or prolactin release relative to earlier secretagogues such as GHRP-6 (Raun et al., 1998). Because ipamorelin is constant across the two blends, it is not the variable that distinguishes them — the GHRH analog is.

The variable component: which GHRH analog

GHRH analogs bind the GHRH receptor on pituitary somatotrophs. Native GHRH is degraded rapidly by dipeptidyl peptidase-4 (DPP-4), so research-stage analogs are engineered for protease resistance and altered half-life. This is where TESA/IPA and CJC/IPA diverge.

Tesamorelin (the GHRH side of TESA/IPA)

Tesamorelin is a stabilized analog of full-length human GHRH(1–44), modified with a trans-3-hexenoic acid group to resist DPP-4 cleavage. In the research and regulatory literature it is one of the most extensively characterized GHRH-receptor agonists, with published preclinical and clinical pharmacology describing GHRH-receptor-mediated stimulation of the somatotroph axis (Ferdinandi et al., 2007). Its structure is close to the endogenous GHRH sequence, which is the feature most often cited to distinguish it from shorter chimeric analogs.

CJC-1295 (the GHRH side of CJC/IPA)

CJC-1295 is a modified GHRH(1–29) fragment — the minimal bioactive GHRH domain — carrying substitutions that reduce enzymatic degradation. Two research forms are widely discussed: a version without the Drug Affinity Complex (“CJC-1295 no-DAC”, functionally comparable to modified GRF(1–29)) and a DAC-conjugated version designed to bind serum albumin and extend circulating half-life substantially in animal models (Teichman et al., 2006). The DAC modification is the defining pharmacokinetic feature of that construct and the main reason the two blends are dosed and studied on different time courses in the literature.

How the two blends differ at a glance

Why the GHRH choice is the key difference

The mechanistic logic of pairing a GHRH agonist with a GHS-R1a agonist is the same for both blends: in preclinical work the two receptor pathways have been observed to act cooperatively on somatotroph signaling, with the GHRH arm and the ghrelin-receptor arm engaging different intracellular cascades (cAMP/PKA versus phospholipase-C pathways) that have been reported to produce additive or synergistic secretagogue signaling in animal and cell models. Because ipamorelin is held constant, any observed difference between TESA/IPA and CJC/IPA in a given study is attributable to the GHRH analog — its structure, its protease resistance, and, for CJC-1295, whether the DAC-extended form is used.

For researchers, three practical distinctions follow from that substitution:

• Structural fidelity to native GHRH. Tesamorelin is built on the full 44-residue GHRH sequence; CJC-1295 is built on the truncated 29-residue fragment. This is the core structural contrast between the blends.
• Pharmacokinetic profile. The DAC option on CJC-1295 can extend the circulating window in animal models far beyond what is reported for tesamorelin or no-DAC constructs, which is why studies of the two blends are not directly interchangeable on a time-course basis.
• Weight of published evidence. Tesamorelin carries a deeper published pharmacology record, whereas much CJC-1295 data sits at the preclinical/pharmacokinetic stage. Researchers weighing the two often factor in this difference in literature depth.

Choosing between them for a research protocol

Selection in a laboratory context generally comes down to which GHRH-receptor pharmacology a study is designed to probe: a full-length, well-characterized GHRH analog (tesamorelin) versus a truncated fragment whose defining research question is often the effect of the DAC half-life extension (CJC-1295). Product-level specifications, purity documentation, and reconstitution arithmetic for either blend can be reviewed in the linked resources below.

Researchers comparing these blends can review the IPA/TESA blend and the Ipamorelin/CJC-1295 blend product pages, or the standalone ipamorelin listing to isolate the shared GHS-R1a component. Purity and identity data are available in the COA library, and laboratory reconstitution math can be worked out with the reconstitution calculator.

Reviewed for research accuracy — published 2026-07-13.

References

• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. PMID: 9849822.
• Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology. 2007;100(1):49–58. PMID: 17214611.
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. PMID: 16352683.
• Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues — a review of GHRH and GHS-R1a pharmacology. Translational Andrology and Urology. 2020;9(Suppl 2):S149–S159. PMID: 32257855.

For research use only. Not for human or veterinary use. The compounds discussed here are intended solely for in vitro and laboratory research by qualified professionals, and nothing above describes or endorses administration to humans or animals.

The following is provided for research and educational purposes only. BAM-15 and SLU-PP-332 are research chemicals intended solely for in vitro and preclinical laboratory use, not for human or veterinary consumption.

Researchers surveying the “exercise-mimetic” and metabolic literature frequently encounter BAM-15 and SLU-PP-332 in adjacent contexts, which invites a direct question: how do BAM-15 and SLU-PP-332 differ? The short answer is that they act at entirely different points in cellular energy metabolism. BAM-15 is a small-molecule mitochondrial uncoupler that operates at the inner mitochondrial membrane, while SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRs), a family of transcription factors. This article compares the two mechanisms as they have been characterized in preclinical models.

What BAM-15 is, in research terms

BAM-15 (chemically an N,N′-substituted fluorodinitroaniline) is described in the literature as a protonophore — a molecule that shuttles protons across the inner mitochondrial membrane, dissipating the proton-motive force that ATP synthase would otherwise use. In cell and animal studies it has been characterized as a mitochondrial uncoupler that reportedly increases oxygen consumption and substrate oxidation without, according to the original characterization, depolarizing the plasma membrane at the concentrations tested. Preclinical reports have examined its effects on mitochondrial respiration and on metabolic parameters in rodent models. Researchers often contrast it with the classical uncoupler 2,4-dinitrophenol (DNP); the published rationale for interest in BAM-15 is a reportedly wider separation between the concentration that uncouples mitochondria and the concentration associated with cytotoxicity in the systems studied.

What SLU-PP-332 is, in research terms

SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), orphan nuclear receptors that regulate transcriptional programs governing mitochondrial biogenesis and oxidative metabolism. Rather than acting directly on the membrane, SLU-PP-332 has been studied as a compound that engages a receptor and, in preclinical models, is associated with changes in the expression of genes linked to oxidative fatty-acid metabolism and mitochondrial function. Because ERRs sit upstream of metabolic gene networks, investigators have described SLU-PP-332 in the exercise-mimetic research context — that is, as a tool to study, in animal and cell systems, some of the transcriptional signatures that physical activity is known to induce. All such findings to date are preclinical.

BAM-15 vs SLU-PP-332: mechanism comparison

How the two mechanisms relate

The most useful way to hold the distinction is that the two compounds have been studied as if they act at opposite ends of the same energy pathway. BAM-15 is characterized as intervening at the physical membrane where the proton gradient is spent, making respiration less efficient in real time. SLU-PP-332 is characterized as intervening at the genome, where the machinery for oxidative metabolism is transcribed. In principle, one alters how existing mitochondria behave, while the other is studied for its association with the expression of mitochondrial and oxidative-metabolism genes. This conceptual complementarity is why some research groups have examined the two mechanisms side by side, and why a combined BAM-15 / SLU-PP-332 research blend exists as a distinct study article. Any combined use remains strictly a preclinical research question; no synergistic outcome should be assumed from the individual literature.

Handling and characterization notes for the laboratory

Both compounds are typically supplied as research powders and require reconstitution in an appropriate solvent for in vitro work; BAM-15 and SLU-PP-332 are both poorly water-soluble and are commonly handled in DMSO stock solutions in published protocols. Any preparation is laboratory arithmetic only and is not a dose for administration. Researchers verifying identity and purity should review the batch certificates of analysis (COAs), and those preparing stock concentrations for assays may find the reconstitution calculator useful for the underlying volume math. Product-level details for each compound are available on the BAM-15 research listing and the SLU-PP-332 research listing.

Summary

BAM-15 and SLU-PP-332 are not interchangeable and are not variants of one another. BAM-15 has been studied as a mitochondrial uncoupler acting biochemically at the inner membrane; SLU-PP-332 has been studied as an ERR agonist acting through transcriptional regulation. Both appear in the preclinical metabolic and exercise-mimetic literature, but they answer different mechanistic questions, and the available evidence for each is limited to in vitro and animal models.

Reviewed for research accuracy — July 13, 2026.

References

• Kenwood BM, et al. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism. 2014;3(2):114–123. PMID: 24634817.
• Alexopoulos SJ, et al. Nature Communications. 2020;11(1):2397. PMID: 32409697. (Title omitted; cited by authors, journal, volume and year.)
• Preclinical studies from the Burris laboratory (Saint Louis University) have characterized SLU-PP-332 as a synthetic pan-ERR agonist and examined its effects on oxidative-metabolism gene expression and exercise-associated transcriptional signatures in rodent models (2023). Consult the primary publications directly for study design and endpoints.
• Reviews of estrogen-related receptor (ERR) biology and mitochondrial biogenesis provide background on the transcriptional pathway targeted by ERR agonists; see current ERR / PGC-1α literature on PubMed.

Research use only. BAM-15 and SLU-PP-332 are not drugs, dietary supplements, or articles for human or animal consumption, and nothing above should be interpreted as medical, therapeutic, or performance guidance. Intended exclusively for licensed research settings.

For laboratory and research use only. The following describes standard laboratory handling of research compounds and is not intended for human or veterinary use, diagnosis, or treatment.

Most research peptides ship as a lyophilized (freeze-dried) powder because the solid state is far more stable than a solution during transit and storage. Before a peptide can be used in an assay it must be reconstituted — dissolved back into a liquid at a known concentration. This guide walks through the materials, the arithmetic, and the storage practices researchers use to prepare a reconstituted stock. For rapid concentration calculations, keep the peptide reconstitution calculator open alongside this page.

What lyophilization is and why it matters

Lyophilization removes water from a frozen peptide under vacuum, leaving a dry cake or film in the vial. In this state peptide bonds and side chains are relatively protected from hydrolysis and oxidation. Reconstitution reverses that: once the powder is back in solution, chemical and enzymatic degradation pathways become active again, which is why reconstituted stocks are handled cold and used within a defined window. Confirming the identity and purity of the starting material against its certificate of analysis — see the COA library — is standard practice before any reconstitution.

Materials researchers typically assemble

• The lyophilized peptide vial, brought to room temperature while still sealed to prevent condensation on the cold powder.
• A reconstitution solvent — most commonly bacteriostatic water (sterile water with ~0.9% benzyl alcohol), which resists microbial growth in multi-draw laboratory vials. Sterile or distilled water is used where a preservative-free solvent is required.
• A graduated syringe or micropipette appropriate to the transfer volume.
• Alcohol wipes for the vial stoppers.
• Labels for recording concentration and preparation date.

Some hydrophobic peptides do not fully dissolve in water and are documented in the literature as requiring a small fraction of a co-solvent (for example dilute acetic acid or bacteriostatic saline) before dilution into the working buffer. The certificate of analysis and published solubility data for the specific sequence should guide solvent choice.

Step-by-step reconstitution procedure

The following describes bench technique for preparing a stock solution; all volumes below are laboratory arithmetic, not administration instructions.

1. Equilibrate. Let both the peptide vial and the solvent reach room temperature.
2. Sanitize. Wipe both rubber stoppers with alcohol and let them dry.
3. Draw the solvent. Withdraw the chosen volume of bacteriostatic water into the syringe (the volume is chosen to hit a target concentration — see the math below).
4. Add slowly. Insert the needle and let the solvent run down the inside wall of the vial rather than jetting directly onto the powder. Peptides are shear-sensitive; a gentle stream limits foaming and denaturation.
5. Dissolve without shaking. Swirl gently or let the vial stand until the cake fully dissolves. Do not vortex or shake vigorously — agitation and air introduction can fragment or aggregate the peptide.
6. Inspect. A properly reconstituted stock is clear and free of visible particulate. Persistent cloudiness suggests incomplete solubility and points back to solvent selection.
7. Label immediately. Record the concentration and date on the vial before it goes into storage.

Concentration math

Reconstitution concentration is simply the mass of peptide in the vial divided by the volume of solvent added:

Concentration = peptide mass ÷ solvent volume

The practical variable a researcher controls is the solvent volume. Adding more water yields a lower concentration and a larger measured volume per unit of peptide; adding less water yields a more concentrated stock. Two worked examples, expressed in milligrams and milliliters:

Concentrations are often converted to micrograms for fine measurements: 1 mg/mL equals 1000 µg/mL, so 0.1 mL of a 1 mg/mL stock contains 100 µg. Rather than working these by hand, the peptide reconstitution calculator takes the vial mass and target concentration and returns the exact solvent volume — the fastest way to avoid an arithmetic error at the bench.

Storage and stability

Storage practice follows the state of the material:

• Lyophilized powder is the most stable form. Sealed and kept cold (refrigerated for short holds, frozen at −20 °C or below for longer holds), many sequences remain stable for months to years, per manufacturer and literature stability data.
• Reconstituted stock is far less stable. Refrigerated at 2–8 °C, most reconstituted peptides are documented as usable for a matter of weeks; the benzyl alcohol in bacteriostatic water suppresses microbial growth but does not stop chemical degradation.
• Freeze–thaw cycles are a known source of degradation. Where a stock will be used over time, researchers commonly aliquot it into single-use fractions so the bulk is thawed only once. Repeated freezing and thawing is associated with peptide fragmentation and loss of measurable activity in stability studies.

Protect vials from light and record the reconstitution date on every label so age can be tracked against the assay timeline.

Common handling errors

• Directing the solvent stream onto the powder or shaking the vial, both of which promote foaming and denaturation.
• Choosing water for a peptide the literature documents as poorly water-soluble, producing a cloudy, incompletely dissolved stock.
• Leaving a reconstituted stock at room temperature between uses.
• Failing to label concentration and date, which makes downstream calculations unverifiable.

References

• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544–575. PMID: 20143256.
• Wang W. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics. 2000;203(1–2):1–60. PMID: 10967427.
• Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharmaceutical Research. 1989;6(11):903–918. PMID: 2687836.
• Preclinical and analytical studies on peptide solubility and reconstitution solvent selection have examined co-solvent requirements for hydrophobic sequences; consult the compound-specific certificate of analysis for documented solubility.

For laboratory and research use only. Not for human or veterinary use. Nothing above is a dosing instruction or a recommendation to administer any compound; all volumes are laboratory calculations for preparing research stock solutions.

The following is provided for research and educational purposes only; the compounds and analytical methods described are intended for laboratory research use only and not for human or animal use.

A Certificate of Analysis (COA) is the primary document a laboratory uses to characterize a research compound before it enters an experiment. For researchers working with synthetic peptides, the COA is where identity, purity, and content are documented against the analytical methods that produced those numbers. Reading one well is a matter of knowing which assay reports which attribute, and what the acceptance criteria on each line actually describe. This guide walks through the four attributes researchers most often need to interpret — identity, purity, net peptide content, and appearance — and explains why independent, third-party testing is a meaningful signal of data quality.

What a COA documents

A COA is a batch-specific record. It is tied to a particular lot number and reports the results of the analytical tests run on material from that lot. Because peptide synthesis is a batch process, results are not transferable between lots: two vials of the same compound can carry different purity and content values if they came from different syntheses. When reading a COA, researchers generally confirm that the lot number on the certificate matches the lot on the vial, that a test date is present, and that each reported attribute is paired with the method used to measure it. A number without a named method — “99% pure” with no chromatogram or assay reference — is not verifiable.

Identity: confirmed by mass spectrometry

Identity answers a single question: is the molecule in the vial the peptide it claims to be? The standard method is mass spectrometry (MS), typically electrospray ionization (ESI-MS) or matrix-assisted laser desorption/ionization (MALDI-TOF). The assay measures the molecular mass of the compound, which is then compared against the theoretical monoisotopic or average mass calculated from the peptide sequence.

On the COA, researchers look for the observed mass reported alongside the expected (theoretical) mass. A close match — usually within a fraction of a mass unit for the monoisotopic value, or the correct value for the most abundant charge state — supports the stated identity. Mass spectrometry confirms the molecular weight; it does not, on its own, prove purity, which is why it is read together with the chromatographic data below. A COA that reports only a purity percentage without any identity confirmation leaves the fundamental identity question unanswered.

Purity: the HPLC-UV main peak

Purity on a peptide COA is almost always determined by reversed-phase high-performance liquid chromatography with ultraviolet detection (RP-HPLC-UV). The sample is separated on a column, and compounds elute at different times. A UV detector records absorbance, producing a chromatogram of peaks. Purity is reported as the area of the main peak as a percentage of the total peak area — often written as “% by HPLC” or “area %”.

Several points help researchers interpret this figure accurately:

• It is a relative measurement. A 98% main peak means the target compound accounts for 98% of the total UV-absorbing area detected, with the remaining 2% attributable to related impurities such as truncated or deletion sequences.
• Detection wavelength matters. Peptides are commonly monitored at 214 nm (peptide bond absorbance) or 220 nm. Impurities that absorb weakly at the chosen wavelength may be under-represented, so the wavelength should be stated.
• A chromatogram is stronger evidence than a number. A COA that includes the actual HPLC trace lets a researcher see peak shape, baseline quality, and the size of neighboring peaks, rather than trusting a single reported value.
• Purity is not content. A high HPLC purity says the peptide fraction is clean; it does not say how much of the vial’s mass is peptide. That is a separate attribute.

Net peptide content

Net peptide content — sometimes called “peptide content” or “net peptide” — reports what fraction of the vial’s total mass is actually peptide. The remainder is typically bound water, residual counter-ions and salts (for example, trifluoroacetate from purification), and other non-peptide material. Content is commonly determined by amino acid analysis (AAA), or estimated by other quantitative methods, and reported as a percentage such as 80–90%.

This distinction is frequently misread. A vial can show 99% HPLC purity and 80% net peptide content at the same time: the peptide present is very clean, but only 80% of the labeled mass is peptide. For researchers performing quantitative work, net peptide content is the figure that governs how much active compound a given mass of powder represents. Laboratory reconstitution arithmetic — calculating concentration from mass and solvent volume — is more accurate when it accounts for net peptide content rather than assuming the full labeled mass is peptide. A reconstitution calculator can assist with this laboratory arithmetic.

Appearance

Appearance is the simplest line on the COA and the easiest to verify by eye. It records the physical description of the material — typically “white to off-white lyophilized powder” for a peptide. While it cannot confirm identity or purity, appearance is a first-pass check: discoloration, clumping in a compound expected to be a dry powder, or a physical form that does not match the certificate can indicate a handling, storage, or labeling problem worth investigating before any analytical work begins.

Why third-party testing matters

A COA is only as trustworthy as the laboratory that produced it. An in-house certificate carries an inherent conflict of interest: the party selling the material is also the party grading it. Independent, third-party analysis — testing performed by a laboratory with no stake in the result — removes that conflict and is a stronger signal of data integrity.

When evaluating who ran the tests, researchers often look for:

Signals of a credible independent report include a named testing laboratory, a stated accreditation (such as ISO/IEC 17025 for testing competence), the analytical methods and instruments used, a lot number, a test date, and — ideally — the raw chromatograms and mass spectra rather than summary numbers alone. Luxe Peptides publishes lot-specific certificates in its COA library, where researchers can cross-check the lot on a vial against the documented identity, purity, and content data for that batch.

Putting it together

Read as a set, the four attributes answer complementary questions: mass spectrometry establishes what the compound is, HPLC-UV establishes how clean the peptide fraction is, net peptide content establishes how much of the mass is peptide, and appearance provides a physical cross-check. A complete, independently produced COA that reports a method and a result for each — and shows its work in the underlying chromatograms and spectra — is the documentation researchers rely on to characterize material before it enters an experiment.

References

• United States Pharmacopeia, General Chapter <621> Chromatography — standard framework for HPLC purity determination.
• United States Pharmacopeia, General Chapter <736> Mass Spectrometry — principles of mass measurement for identity confirmation.
• ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories — the accreditation standard commonly cited for independent analytical laboratories.
• Peer-reviewed methodological reviews on reversed-phase HPLC and mass spectrometric characterization of synthetic peptides (for example, in Journal of Chromatography A) describe the main-peak purity and identity workflows summarized here.

Research use only. The information and analytical methods described are for laboratory research and educational purposes and are not intended to diagnose, treat, or otherwise be used with humans or animals.

The following is provided for laboratory research use only; the compounds discussed are not approved for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any condition.

Growth hormone (GH) secretagogues are a class of molecules studied for their ability to stimulate GH release through the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous peptide ghrelin. Three compounds recur throughout the preclinical literature: GHRP-6, MK-677 (ibutamoren), and Ipamorelin. Although researchers group them together by receptor target, they differ substantially in chemical class, selectivity, and the secondary hormonal responses observed in research models. This article compares the three on mechanism and research profile only.

Shared mechanism: the GHS-R1a pathway

All three compounds are studied as agonists of GHS-R1a, a G-protein-coupled receptor expressed in the hypothalamus and pituitary. In research models, activation of this receptor is associated with pulsatile GH release from somatotroph cells and, indirectly, with modulation of somatostatin tone. Because the receptor is the ghrelin receptor, investigators frequently examine these secretagogues alongside ghrelin biology. The mechanistic distinction between the three lies less in which receptor they engage and more in their selectivity for GH release versus the co-secretion of other pituitary and adrenal hormones, and in their pharmacokinetic behavior.

GHRP-6: the first-generation peptide

GHRP-6 is a synthetic hexapeptide and one of the earliest growth hormone-releasing peptides characterized in the literature. In preclinical and early human investigational studies, GHRP-6 has been observed to stimulate GH release; it is also noted in the research record for its associated effects on other axes. Studies indicate that GHRP-6 administration is associated with increases in cortisol and prolactin, and it has been widely used in research as a probe of ghrelin-mediated signaling, including its broader ghrelin-receptor signaling profile in animal models. This broader secondary profile is a defining feature that later secretagogues were designed to reduce. Researchers sourcing this peptide can review the GHRP-6 product page for specifications.

Ipamorelin: a selective pentapeptide

Ipamorelin is a synthetic pentapeptide developed specifically to improve GH selectivity relative to earlier GHRPs. In the foundational preclinical characterization, Ipamorelin was reported to stimulate GH release with a potency comparable to GHRP-6 but without the marked elevations in ACTH and cortisol observed with the earlier peptide, and with minimal effect on prolactin (Raun et al., 1998). This selectivity is the principal reason Ipamorelin appears frequently in research designs where investigators wish to isolate GH-axis effects from confounding adrenal or prolactin responses. As a peptide, it shares the injectable-research-format and relatively short duration of action characteristic of the GHRP family. Specifications are available on the Ipamorelin product page.

MK-677 (ibutamoren): the orally active non-peptide

MK-677, also called ibutamoren, differs from the other two in a fundamental way: it is not a peptide but a small-molecule, spiropiperidine-based GHS-R1a agonist. Its defining research characteristics are oral bioavailability and a substantially longer duration of action. In clinical research settings, MK-677 has been reported to produce sustained increases in GH and IGF-1 concentrations, with studies examining sustained daily exposure in investigational contexts. Because its half-life supports prolonged receptor engagement, MK-677 is studied where a longer, more continuous elevation of the GH/IGF-1 axis is the variable of interest, in contrast to the pulsatile stimulation associated with the injectable peptides.

Comparison table

How researchers frame the distinctions

The three compounds are best understood as points along two axes rather than as substitutes for one another. The first axis is selectivity: GHRP-6 sits at the less-selective end, with a research record of co-secretion of cortisol and prolactin, while Ipamorelin was engineered toward the selective end for GH-axis isolation. The second axis is pharmacokinetics and route: the two peptides act briefly and are handled in injectable research formats, whereas MK-677 is orally active with a long duration, making it distinct in study designs concerned with sustained IGF-1 elevation. A researcher designing an experiment on pulsatile GH signaling, an experiment isolating GH from adrenal confounders, and an experiment on prolonged axis stimulation would plausibly select GHRP-6, Ipamorelin, and MK-677 respectively.

For laboratory handling, reconstitution of the peptide compounds is straightforward arithmetic based on the desired concentration and the diluent volume; the reconstitution calculator assists with that math, and batch-specific analytical data is published in the COA library.

Reviewed for research accuracy

Reviewed for research accuracy on 2026-07-11. Statements describe findings reported in preclinical and investigational literature and are not claims about outcomes in humans.

References

• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. PMID: 9849822.
• Bowers CY. Growth hormone-releasing peptide (GHRP). Foundational pharmacology of the GHRP family, including GHRP-6, described across the endocrinology literature.
• Clinical and preclinical investigations of MK-677 (ibutamoren) have examined its oral bioavailability and sustained effects on the GH/IGF-1 axis; see the peer-reviewed endocrinology literature on non-peptide growth hormone secretagogues.

Research use only. The compounds discussed are intended solely for laboratory research and are not for human or veterinary use, consumption, or administration of any kind.